|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Descriptive Information Fields | |||||
| Brief Title † | Memory Imaging of Normal Aging | ||||
| Official Title † | BOLD and Perfusion fMRI of Alzheimer's Disease Risk | ||||
| Brief Summary | The purpose of this study is to develop imaging techniques that can distinguish functional brain changes in people at high risk for dementia years prior to onset of clinical memory problems from those with normal changes of aging. |
||||
| Detailed Description | The overall goals of this project are to identify consistent patterns of variance in brain function in patients at risk for Alzheimer's Disease by using APOE ε4 as a marker for disease risk. The activation Blood Oxygen Level Dependency (BOLD) signal will be compared to both resting and activation perfusion signals to assess the variability of cerebral blood flow as it relates to the BOLD signal. Each participant will be imaged on a 3T MRI scanner while performing an associate episodic memory task. A total of 90 individuals will be recruited for this study. Participants will be non-demented, right handed, adults with or without at least one APOE ε4 allele. Groups will be split as follows: A) ages 25-39: non-ε4 (n=15); B) ages 25-39: +ε4 (n=15); C) ages 40-49: non-ε4 (n=15); D) ages 40-49: +ε4 (n=15);.E) ages 50-65: non-ε4: F) ages 50-65: +ε4 (n=15). These groups will be matched for mean age, mean years of education, gender distribution, as well as the presence or absence of a family history of AD in a first degree relative. There will be 2 scanning sessions for each participant. Scan session #1 and Scan session #2 will be acquired within 2 weeks of each other and will take approximately one hour each. |
||||
| Study Phase | |||||
| Study Type † | Observational | ||||
| Study Design † | Cohort, Cross-Sectional | ||||
| Primary Outcome Measure † | identification of consistent patterns of variance in brain function in subjects at risk for Alzheimer's Disease by using APOE ε4 as a marker for disease risk [ Time Frame: single time point ] [ Designated as safety issue: No ] | ||||
| Secondary Outcome Measure † | |||||
| Condition † | Alzheimer's Disease | ||||
| Intervention † | Procedure: BOLD and Perfusion brain MRI | ||||
| MEDLINE PMIDs | 10944562, 8498827, 16344346, 15956166 | ||||
| Links | |||||
| Recruitment Information Fields | |||||
| Recruitment Status † | Recruiting | ||||
| Enrollment † | 90 | ||||
| Start Date † | August 2005 | ||||
| Completion Date | July 2009 | ||||
| Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | 25 Years to 65 Years | ||||
| Accepts Healthy Volunteers | Yes | ||||
| Contacts †† |
|
||||
| Location Countries † | United States | ||||
| Administrative Information Fields | |||||
| NCT ID † | NCT00315575 | ||||
| Organization ID | IA0092 | ||||
| Secondary IDs †† | 5K23AG024062-02 | ||||
| Study Sponsor † | National Institute on Aging (NIA) | ||||
| Collaborators †† | |||||
| Investigators † |
|
||||
| Information Provided By | National Institute on Aging (NIA) | ||||
| Verification Date | December 2007 | ||||
| First Received Date † | April 14, 2006 | ||||
| Last Updated Date | December 14, 2007 | ||||